All AbMole products are for research use only, cannot be used for human consumption.
Methylproamine is a DNA-binding radioprotector which, on the basis of published pulse radiolysis studies, acts by repair of transient radiation-induced oxidative species on DNA. IC50 Value: N/A Target: DNA-binding radioprotector in vitro: The extent of radioprotection at the clonogenic survival endpoint increased with methylproamine concentration up to a maximum dose modification factor (DMF) of 2.0 at 10 μM. At least 0.1 fmole/nucleus of methylproamine is required to achieve a substantial level of radioprotection (DMF of 1.3) with maximum protection (DMF of 2.0) achieved at 0.23 fmole/nucleus. The γH2AX focus yield per cell nucleus 45 min after irradiation decreased with drug concentration with a DMF of 2.5 at 10 μM. Methylproamine-treated cells had fewer γH2AX foci after IR compared to untreated cells. Also, the presence ofmethylproamine decreased the amount of lower molecular weight DNA entering the gel as shown by the pulsed field gel electrophoresis assay. Experiments with V79 cells have shown that methylproamine is approximately 100-fold more potent than the classical aminothiol radioprotector WR1065. The crystal structures of methylproamine and proamine complexes with the dodecamer d(CGCGAATTCGCG)(2) confirm that the new analogues also are minor groove binders. in vivo: N/A Clinical trial: N/A
| Molecular Weight | 465.59 |
| CAS Number | 188247-01-0 |
| Solubility (25°C) | DMSO ≥ 41 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Kenan Barut, et al. Balkan Med J. Juvenile Idiopathic Arthritis
| Related Products |
|---|
| DSPE-PEG-FA
DSPE-PEG2K-FA is a PEG derivative containing folic acid. DSPE-PEG2K-FA has a targeting effect and can bind to folic acid receptors in cancer cells. DSPE-PEG2K-FA forms micelles/lipid bilayers and can be used in research on targeted drug delivery systems. |
| Lifastuzumab
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. |
| GPVI antagonist 1
GPVI antagonist 1 is a glycoprotein VI (GPVI) platelet receptor antagonist. GPVI antagonist 1 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM. |
| MPSD TFA
MPSD TFA (MARCKS-ED TFA) is a 25-amino acid peptide based on the effector domain sequence of the intracellular membrane protein myristoylated alanine-rich C-kinase substrate (MARCKS). MPSD TFA can sense membrane curvature and recognize phosphatidylserine. MPSD TFA can be utilized as biological probe to study membrane shape and lipid composition. |
| 4-Nitro-2,1,3-benzoselenadiazole
4-Nitro-2,1,3-benzoselenadiazole is a biochemical material that can be used in scientific research. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
